EW · Edwards Lifesciences Corporation — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on EW. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About EW · Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Live Quote
HOLD (score +2) · 12-1 mom 9.7% · RSI 54.4 · above_both · -1.8% from high
Targets blend Wall Street consensus (26 analysts: low $84.00 / mean $96.92 / high $110.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
The Form 4 cluster triggered by the pipeline is almost entirely routine compensation activity — RSU grants and option exercises for executives, plus standard director equity awards. The sole exception is Scott Ullem (outgoing CFO), who has been selling shares via a pre-established 10b5-1 plan at ~$80 since April while preparing to exit his role by end of May. No open-market purchases (P-code trades) from any executive or director were found in the investigation window. The stock is technically oversold (RSI 37, below both MAs), sitting ~12% off its 52-week high after a recent sell-off, with Q1 2026 results having beaten and raised full-year guidance — but at forward P/E of 22.9x vs sector peers, EW is fairly valued rather than mispriced.
Lessons Referencing This Ticker
In low-float, high-short-interest commodity names (~10%+ shorts), pre-earnings positioning can cause large directional spikes (10-15%) that distort entry pricing and skew readings. These spikes are driven by gamma positioning and short-covering, not fundamental information. Enter spreads AFTER the pre-event spike resolves, not before.
extracted Jun 19, 2026 from 2026-06-01-UEC-earnings-put-spread
In commodity-linked names with institutional holders, put skew is often driven by hedging activity (portfolio insurance, commodity price exposure) rather than directional bearishness. Elevated put skew in these names should be discounted as a signal and treated as structural, not informational.
extracted Jun 19, 2026 from 2026-06-01-UEC-earnings-put-spread
RSI(14) > 80 is a valid overbought signal that should reduce the technical_was_useful score and trigger a mean-reversion warning. In the scoring methodology, technical signals should not be dismissed as 'Tier 3 confirmation' when they indicate extreme conditions.
extracted Jun 19, 2026 from 2026-06-01-PANW-earnings-debit-call